Cargando…

Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine

The combination of platinum and gemcitabine is one of the standard regimens in the treatment of advanced lung squamous carcinoma (LSC). Resistance to gemcitabine is main barrier to the successful treatment of LSC. In this study, we showed that suppression of the Fanconi anemia (FA) pathway increased...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dai, Chun-Hua, Wang, Yi, Chen, Ping, Jiang, Qian, Lan, Ting, Li, Mei-Yu, Su, Jin-Yu, Wu, Yan, Li, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678185/ https://www.ncbi.nlm.nih.gov/pubmed/29118324 http://dx.doi.org/10.1038/s41598-017-15172-4

Ejemplares similares

Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine
por: Goss, Kelli L, et al.
Publicado: (2017)

BRD7 suppresses tumor chemosensitivity to CHK1 inhibitors by inhibiting USP1-mediated deubiquitination of CHK1
por: Li, Lemin, et al.
Publicado: (2023)

Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancer
por: Dufau, Isabelle, et al.
Publicado: (2012)

Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor
por: Montano, Ryan, et al.
Publicado: (2017)

CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors
por: Chen, Clark C, et al.
Publicado: (2009)

Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine
por: Oo, Zay Yar, et al.
Publicado: (2019)

Chk1 suppressed cell death
por: Meuth, Mark
Publicado: (2010)

A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer
por: Jones, Robert, et al.
Publicado: (2023)

γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments
por: Rawlinson, Rebecca, et al.
Publicado: (2014)

Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine
por: Duong, Hong-Quan, et al.
Publicado: (2013)

Keeping RelApse in Chk: molecular mechanisms of Chk1 inhibitor resistance in lymphoma
por: Black, Elizabeth M., et al.
Publicado: (2022)

Chk-mate on resistance to kinase inhibitors
por: Shapiro, Paul
Publicado: (2018)

Chk1, Chk2, is the amplifier on?
por: Dove, Alan W.
Publicado: (2001)

Tumour growth environment modulates Chk1 signalling pathways and Chk1 inhibitor sensitivity
por: Massey, Andrew J.
Publicado: (2016)

Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo
por: Montano, Ryan, et al.
Publicado: (2013)

Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer
por: Nair, Jayakumar, et al.
Publicado: (2020)

Clinical and functional significance of CHK1-S, an alternatively spliced isoform of the CHK1 gene, in hepatocellular carcinoma
por: Hu, Guanghui, et al.
Publicado: (2020)

TRIM21 suppresses CHK1 activation by preferentially targeting CLASPIN for K63-linked ubiquitination
por: Zhu, Xuefei, et al.
Publicado: (2022)

FaGAPC2/FaPKc2.2 and FaPEPCK reveal differential citric acid metabolism regulation in late development of strawberry fruit
por: Yang, Min, et al.
Publicado: (2023)

The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel‐resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe
por: Drápela, Stanislav, et al.
Publicado: (2020)

The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor
por: Liang, Xiaobing, et al.
Publicado: (2011)

A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors
por: Di Giulio, Stefano, et al.
Publicado: (2021)

The Combination of ATM and Chk1 Inhibitors Induces Synthetic Lethality in Colorectal Cancer Cells
por: Tozaki, Yuri, et al.
Publicado: (2023)

A Kinome Screen Identifies Checkpoint Kinase 1 (CHK1) as a Sensitizer for RRM1-Dependent Gemcitabine Efficacy
por: Zhou, Jun, et al.
Publicado: (2013)

Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation
por: Yu, Xinfang, et al.
Publicado: (2020)

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2021)

Dominant mutations in CHK1 cause pronuclear fusion failure and zygote arrest that can be rescued by CHK1 inhibitor
por: Zhang, Honghui, et al.
Publicado: (2021)

Kodamaeahongheensis f.a., sp. nov., Kodamaeaovata f.a., sp. nov. and Kodamaeayamadae f.a., sp. nov., three new yeast species of Kodamaea (Saccharomycetales, Debaryomycetacae) from China
por: Chai, Chun-Yue, et al.
Publicado: (2022)

PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells
por: Liu, Chuan, et al.
Publicado: (2020)

Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts
por: Yang, Chia-Yu, et al.
Publicado: (2020)

Clustering PPI data by combining FA and SHC method
por: Lei, Xiujuan, et al.
Publicado: (2015)

The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia
por: Di Tullio, Alessandro, et al.
Publicado: (2017)

Suppression of Human T Cell Proliferation Mediated by the Cathepsin B Inhibitor, z-FA-FMK Is Due to Oxidative Stress
por: Rajah, Tanuja, et al.
Publicado: (2015)

Targeting Chk1 in the replicative stress response
por: Dai, Yun, et al.
Publicado: (2010)

Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia
por: Rorà, Andrea Ghelli Luserna Di, et al.
Publicado: (2016)

Specific inhibitor of Notch-3 enhances the sensitivity of NSCLC cells to gemcitabine
por: Hu, Bi-Dan, et al.
Publicado: (2018)

NVP-BEZ235, a dual PI3K-mTOR inhibitor, suppresses the growth of FaDu hypopharyngeal squamous cell carcinoma and has a synergistic effect with Cisplatin
por: Hsu, Cheng-Ming, et al.
Publicado: (2018)

Regulation of Chk1
por: Tapia-Alveal, Claudia, et al.
Publicado: (2009)

The blue light signal transduction module FaCRY1-FaCOP1-FaHY5 regulates anthocyanin accumulation in cultivated strawberry
por: Liu, Yongqiang, et al.
Publicado: (2023)

ATM Inhibitor Suppresses Gemcitabine-Resistant BTC Growth in a Polymerase θ Deficiency-Dependent Manner
por: Pan, Yi-Ru, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5dmeo72b8u0h2ql4s1j8drtngu